News
Caplin Point Labs acquires 10 ANDAs, targets $473M US market
The portfolio, purchased from a leading multinational generic manufacturer, addresses a market valued at $473.2 million for the 12 months ending August 2025
- By IPP Bureau
| January 03, 2026
Caplin Point Laboratories has announced a major expansion move, acquiring 10 approved ANDAs for injectable and ophthalmic products through its subsidiaries, Caplin Steriles Limited (CSL) and Caplin One Labs Limited (COL).
The portfolio, purchased from a leading multinational generic manufacturer, addresses a market valued at $473.2 million for the 12 months ending August 2025.
Commenting on the deal, Chairman Mr. C.C. Paarthipan said, "The U.S. market remains a key growth engine for the Company, and this acquisition meaningfully accelerates our strategy by expanding and strengthening our portfolio in the region.
"The acquired portfolio also includes select oncology injectables, which will be transferred to and commercialized from our new dedicated oncology facility in Kakkalur. In addition, we intend to progressively extend these products to key non-U.S. markets, including Mexico, Canada, the European Union, and Brazil."
The acquisition positions Caplin Point Labs to boost its US footprint while leveraging its new oncology facility to drive growth in high-value therapeutic segments.
,_Thyrocare.jpg)
